Research location
Tokyo, Toshima-ku
Japan
Advertisement
Research activity in Tokyo, Toshima-ku
JapanCureCurrent currently publishes aggregate city-level research activity for this location: 9 trials and 9 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Tokyo, Toshima-ku
9 linked trials · page 1 of 1A Study to Test Whether Survodutide Helps Japanese People Living With Obesity DiseaseNCT06176365 · 2024-01-16 · 1 site observation
COMPLETED
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX StudyNCT05211947 · 2022-03-21 · 1 site observation
TERMINATED
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)NCT04846868 · 2021-09-08 · 1 site observation
COMPLETED
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With DepressionNCT04521478 · 2020-11-20 · 1 site observation
COMPLETED
A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 YearsNCT04531462 · 2020-10-05 · 1 site observation
COMPLETED
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)NCT03057977 · 2017-03-06 · 1 site observation
COMPLETED
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)NCT03057951 · 2017-03-02 · 1 site observation
COMPLETED
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes MellitusNCT02489968 · 2015-05-12 · 1 site observation
COMPLETED
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.NCT02296138 · 2015-01-13 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.